Accelerate Diagnostics, Inc. (AXDXQ)

Market Cap	25.00
Revenue (ttm)	11.70M -3.0%
Net Income	-50.05M
EPS	-2.15
Shares Out	25.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,246
Average Volume	100,209
Open	0.0000
Previous Close	0.0000
Day's Range	0.0000 - 0.0000
52-Week Range	n/a
Beta	-0.23
RSI	32.35
Earnings Date	Sep 18, 2025

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjuncti...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1982
• Employees: 107
• Stock Exchange: OTCMKTS
• Ticker Symbol: AXDXQ

Financial Performance

In 2024, Accelerate Diagnostics's revenue was $11.70 million, a decrease of -2.99% compared to the previous year's $12.06 million. Losses were -$50.05 million, -18.78% less than in 2023.